Often caused by mistakes that are left uncorrected when DNA has been copied in a cell, microsatellite instability (MSI) is a condition that occurs in a certain type of cell, such as a cancer cell, where regions of the repeated DNA alter in length, showing instability due to a defect in mismatch repair DNA proteins. Since the errors go uncorrected, they accumulate and through DNA replication, the sequences are not preserved, ultimately creating new microsatellites.
-
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
SEP 28, 2023 12:30 PM CEST
Dr Philippe Taniere – Understanding biomarker testing for immunotherapy; PD-L1 (Programmed Death-Ligand 1) expression, Mismatch Repair (MMR) testing and the importance of Microsatellit...
Date: May 31, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Introducing Nanostring’s latest spatial platform, CosMx Spatial Molecular Imager (SMI). Offering high-plex, multiomi...
Cancer is a disease of the genome, and as such, tools that can analyze the genome are instrumental in understanding the mechanisms that lead to cancer, detecting cancerous cells, and providi...
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Microsatellite instability (MSI) is a hypermutation phenotype that results from impaired DNA mismatch repair (MMR). The presence of high levels of MSI (MSI-H) is potentially predictive of Ly...
DATE: May 8, 2020 TIME: 8:00am PT, 11:00am ET Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indic...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...